ClinicalTrials.gg
Status unknownNCT02892370Updated Sep 8, 2016

Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects

A Phase 1 interventional study of SHR0302 in Rheumatoid Arthritis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
9th of 11
14 · median 30
Started
2016
with 1 other
Phase 1
8 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd., this one is the 9th largest by planned enrollment, is one of 2 that started in 2016, is one of 8 in phase 1, and was the 3rd registered.

Arthritis, Rheumatoid

3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Where they have run

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Arthritis, Rheumatoid by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The purpose of this open-label, randomized, two-period, two-treatment (single doses of 10 mg SHR0302 fasted or fed), crossover study was to evaluate the effect of a high-fat meal on the pharmacokinetics of SHR0302 and mass balance study in 14 healthy subjects.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male
  • :19-24 kg/m2, weight > 50 kg.
  • Age:18-45

Exclusion criteria

Exclusion Criteria:

  • History of laboratory results or disease.
  • History of alcohol or drug abuse.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    SHR0302 fasted to fed

    SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast

    Drug: SHR0302

  • Experimental
    SHR0302 fed to fasted

    SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting

    Drug: SHR0302

Interventions

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax) of SHR0302

    up to 72 hrs postdose on day1 and day7

    Time frame: up to 72 hrs postdose

  2. The area under the plasma concentration-time curve (AUC) of SHR0302

    up to 72 hrs postdose on day1 and day7

    Time frame: up to 72 hrs postdose

  3. The accumulative excretion rate of SHR0302 and its metabolites in urine and feces

    up to 96 hrs postdose on day1 and day7

    Time frame: up to 96 hrs postdose

Secondary outcomes

  1. The number of volunteers with adverse events as a measure of safety

    required last visit via telephone during D11 to D21

    Time frame: up to Day 21

07

Study locations

1 of 1 sites recruiting
  • Shanghai Xuhui Central Hospital
    Shanghai, Shanghai 200030, China
    Recruiting
    • Chen Yu · Contact86-21-54030254
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Sep 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2016
First posted
Sep 8, 2016
Start
Aug 2016
Primary completionEst.
Sep 2016
CompletionEst.
Oct 2016
Last update
Sep 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02892370
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Aug 2016
Primary completion
Sep 2016 (estimated)
Completion
Oct 2016 (estimated)
Last update
Sep 8, 2016

Study contacts

Chengyu Guan, MD
Contact
guanchengyu@hrs.com.cn
86-21-50118402
Chen Yu, BS
principal investigator · Shanghai Xuhui Central Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion